Autoantigens targeted in scleroderma patients with vascular disease are enriched in endothelial lineage cells. Expression of scleroderma autoantigens IFI16 and CENPs, which are associated with severe vascular disease, is increased in vascular progenitors and mature endothelial cells. PubMed, 05/09/2016. (Also see Vascular Involvement in Systemic Scleroderma)
Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis. Among patients with systemic sclerosis and active ischemic digital ulcers, treatment with macitentan did not reduce new digital ulcers over 16 weeks. Journal of the American Medical Association, 05/10/16. (Also see Treatments for Digital Ulcers)
Negatively–charged (NTC) amino acids at the peptide–binding pocket of HLA–DPB1 alleles are associated with susceptibility to anti–opoisomerase I (ATA)–positive systemic sclerosis (SSc). ATA–positive SSc patients share NCTs at the peptide–binding groove of HLA–DPB1 molecules. PubMed, Hum Immunol, 05/18/2016. (Also see Causes of Scleroderma: Genetics)
The role of asymmetric dimethylarginine (ADMA) alone and in combination with N–terminal pro–B–type natriuretic peptide as a screening biomarker for systemic sclerosis–related pulmonary arterial hypertension (SSc–PAH): A case control study. In this small study, use of ADMA in combination with NT–proBNP produced excellent sensitivity and specificity for the non–invasive identification of SSc–PAH. PubMed, Clin Exp Rheumatol, 05/23/2016. (Also see Prognosis of Pulmonary Hypertension in Systemic Sclerosis)
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. The difference was greater in the tocilizumab group than in the placebo group and we found some evidence of less decline in forced vital capacity. The efficacy and safety of tocilizumab should be investigated in a phase 3 trial before definitive conclusions can be made about its risks and benefits. PubMed, Lancet, 05/05/2016. (Also see Clinical Trials)
Scleroderma Mouse Study Suggests Estrogen Therapy Might Slow Skin Fibrosis. The study confirmed that estrogens play a role in protecting against skin fibrosis in experimental models representative of systemic sclerosis and the next step will be to begin investigating the potential role of hormone therapies as a treatment. Scleroderma News, 06/13/2016. (Also see Skin Fibrosis)
Scleroderma Heart Disease Deaths Might Be Prevented with Heart Monitor. Magnetic resonance imaging (MRI) confirmed rhythm changes in both the upper and lower chambers of the heart, as well as an abnormally fast heart rate and complete heart block which was shown on the heart monitors. Scleroderma News, 06/10/2016. (Also see Diagnosis of Systemic Scleroderma Heart Involvement)
Phase 3 Trial to Begin for Terguride in Diffuse Cutaneous Scleroderma. The German pharmaceutical company Medac, in August, will begin Phase 3 of a clinical trial to access the therapeutic potential of terguride, a disease–modifying drug for the treatment of diffuse cutaneous systemic sclerosis. Scleroderma News, 06/09/2016. (Also see Scleroderma Clinical Trials)
One decade distinct features, morbidity and mortality of scleroderma: a cross-sectional study. This study is the first epidemiologic survey on Iranian scleroderma patients with significantly large sample size compared to previous studies worldwide. PubMed, Clin Exp Rheumatol, 06/15/2016. (Also see Scleroderma Research)
Calcinosis in systemic sclerosis (SSC): subsets, distribution and complications. Our data indicate that calcinosis may be classified in SSc as mousse, stone, net and plate according to its clinical and X–ray features. Oxford Journals Rheumatology, 05/30/2016. (Also see Calcinosis)
United Way of Central New Mexico
United Way of Snohomish County
See ISN News for recent donors, including Pam Hop, Margaret Roof, Winifred Schillberg, Arnold Slotkin, and Juliet Youkhana. Plus donations in honor of Kim Thwaits, and in loving memory of Marta Marx, Jim Miller, and Arlene Marie Petulla.
Click Here to Donate or Shop
or click on the floating green DONATE sclero.org button.
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: